Vultin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vultin

Vultin is a prescription-only medication whose active substance is Gabapentin, a synthetic compound structurally related to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is primarily classified as an Anticonvulsant (Antiepileptic Agent) and belongs to the Gabapentinoid pharmacological class.

What Type of Drug is Vultin? (Identity and Classification)

Vultin is categorized as an antiepileptic agent, a drug type used to stabilize abnormal electrical signaling in the central nervous system. The core substance, Gabapentin, is a small molecule recognized for its role in managing nerve hyperexcitability, a key feature in chronic pain. Gabapentin’s primary function involves binding to the auxiliary alpha-2-delta subunits of voltage-gated calcium channels, a distinct mechanism that supports its classification as a gabapentinoid.

Composition and Available Forms (Substance and Preparation)

The composition of Vultin is a single-ingredient product, containing the active pharmaceutical ingredient Gabapentin alongside necessary excipients. For oral administration, this medication is provided in several dosage forms, including standard capsules, tablets, and a liquid oral solution. Specialized preparations, such as extended-release tablets, may also be available, which utilize modified delivery profiles to manage how the substance is absorbed by the body.

What is the General Purpose of This Medication? (Core Benefit)

The general therapeutic purpose of Vultin is to dampen over-excited nerve activity by inhibiting the release of certain excitatory neurotransmitters. By achieving this nerve stabilization, the medication is used to relieve the burning or stabbing pain associated with damaged nerves, such as pain following a shingles outbreak. This medicine works by altering the way the body processes pain signals and decreasing abnormal excitement in the brain. This therapeutic approach supports both antiepileptic action and analgesic action by stabilizing hyper-excitable neurons.

What side effects are possible with Vultin?

Possible side effects and safety information

The safety profile of Vultin (Gabapentin) is officially documented by regulatory authorities, with adverse reactions generally classified by frequency and affected organ system. This information is based solely on data from prescribing information (SmPC/FDA labeling).

Frequency-Classified Adverse Reactions

The most frequently reported effects relate to the central nervous system:

  • Very Common (ge 10%): Dizziness and Somnolence (Drowsiness/Sedation) are the two most commonly reported adverse reactions.
  • Common (ge 1%): Ataxia (Lack of muscle coordination), Fatigue, Peripheral Edema (Swelling of extremities), Nystagmus (Involuntary eye movement), and Nausea or Vomiting are reported as common side effects. Hostility is a common reaction noted in the pediatric population.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for severe, albeit rare, reactions. These include warnings for Suicidal Thoughts and Behavior associated with antiepileptic use and the risk of life-threatening Respiratory Depression, particularly when the medicine is co-administered with other central nervous system depressants. Serious hypersensitivity reactions, such as DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) and Anaphylaxis, are also officially documented.

Specific safety considerations are noted for certain groups. Caution is warranted in older adults, who may experience an increased incidence of adverse effects and a higher risk for respiratory depression. Patients with renal impairment require particular attention, as the drug's elimination via the kidneys necessitates official dosage adjustment guidance.

Additionally, regulatory safety constraints state that the medication should not be abruptly discontinued in patients with seizure disorders, as this carries a documented risk of increased seizure frequency.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory description of Vultin (Gabapentin) overdose centers on manifestations of increasing central nervous system (CNS) depression. Documented clinical presentations may include profound somnolence and lethargy, severe dizziness, and impaired motor control, known as ataxia. Other specific signs listed in official labeling include slurred speech, double vision, and episodes of diarrhea.

Overdose is associated with the potential for life-threatening outcomes, notably the risk of severe respiratory depression (serious breathing difficulties), unresponsiveness, and progression to coma. Regulatory authorities specifically highlight that this severe risk is heightened for elderly patients and individuals with underlying respiratory impairment, or when Vultin is co-administered with other CNS depressants.

Immediate medical attention is required upon observing any sign of severe CNS depression or respiratory compromise, such as difficulty breathing, a state of unresponsiveness, or bluish-colored skin. The management approach described in official documents is symptomatic and supportive. Regulatory statements confirm that no specific antidote is known for Vultin overdose. Procedures such as hemodialysis are documented as an option to remove the drug from the bloodstream in certain cases, particularly for patients with severe renal impairment. Close observation and monitoring are mandated during this period.

Therapeutic Uses of Vultin

What Vultin Treats: Main Uses and Benefits

Vultin is used in areas where short-term symptom management is appropriate, particularly in contexts marked by increased discomfort or tension. This medicine is considered relevant across several areas where additional symptomatic support is needed, providing support that helps ease the overall symptom load. It is considered relevant in conditions presenting with symptoms of increased neurological or muscular activity, such as certain distressing symptoms related to physical discomfort or episodic changes.

The medication is applied in scenarios where additional management of discomfort is required, particularly during phases when symptoms become more noticeable. In clinical contexts involving heightened systemic burden, Vultin supports general well-being during symptomatic phases.

“Vultin is used in areas where short-term symptom management is appropriate to help patients cope more steadily.”


Quick Fact

Quick Fact: Relief for Neurological Discomfort Vultin is relevant in conditions characterized by periods of heightened symptoms and assists with maintaining comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information on Gabapentin

Eligibility and Restrictions for Use

Eligibility Profile of Vultin (Gabapentin)

Official regulatory documents define strict criteria for the use of this medicine. Vultin is absolutely contraindicated in patients with a demonstrated hypersensitivity or allergy to the drug or any of its components. Additionally, individuals who have previously experienced a severe cutaneous adverse reaction (SCAR) such as Stevens-Johnson syndrome (SJS) or Drug reaction with eosinophilia and systemic symptoms (DRESS) with Vultin must not restart treatment.

Use is restricted or conditional in several populations:

  • Renal Impairment: Dosage must be adjusted based on the patient's renal function (creatinine clearance). For severe impairment or patients on hemodialysis, the standard dose is unsuitable and specific regimens apply.
  • Age Groups: Adults and children 3 years of age and older are eligible for use in certain indications. Special consideration is given to the elderly due to the higher likelihood of reduced renal function.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. The medicine is secreted into human milk, meaning use while breastfeeding is only recommended if the benefits clearly outweigh the risks to the infant.
  • Seizure Type: Use should be approached with caution in patients with mixed seizures that include absences, as Vultin may worsen these specific seizures.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Vultin (Gabapentin) as detailed in government regulatory sources. Vultin is not documented to be metabolized by the CYP450 enzyme system, and therefore does not inhibit or induce major hepatic enzymes.

Pharmacodynamic and Absorption Interactions

The primary documented interaction is a pharmacodynamic effect with other Central Nervous System (CNS) depressants, including opioids and alcohol. Co-administration increases the officially noted risk of additive CNS depression, such as somnolence. This additive effect may increase the risk of respiratory depression.

A key administration constraint involves aluminum- and magnesium-containing antacids. Co-administration reduces Vultin's maximum plasma concentration, a pharmacokinetic outcome that requires mandatory separation. Vultin must be administered at least two hours after the administration of these antacids.

Official Exposure-Modifying Statements

Official labeling also documents specific exposure modifications with other medicines. Co-administration with hydrocodone is noted to decrease the Cmax and AUC of hydrocodone. Conversely, cimetidine co-administration causes a slight decrease in Vultin's renal clearance, resulting in a minor official increase in Vultin plasma concentrations. This elevated exposure risk is more pronounced in elderly patients and individuals with impaired renal function due to slower drug clearance.

Mechanism of Action

Vultin’s action is defined by a distinct, non-GABAergic mechanism that targets nerve cells, leading to a dampening of neuronal hyperexcitability and stabilization of electrical signaling.

Targeted Modulation of Presynaptic Calcium Channels

Vultin binds with high affinity to the auxiliary alpha2delta-1 subunit of certain Voltage-Gated Calcium Channels (VGCCs) found on nerve endings . This interaction modulates the function of these channels, resulting in a reduction in the crucial influx of Ca^2+ ions when the nerve fires. This action is independent of direct interaction with GABA receptors, which is distinct from the mechanism of traditional GABA receptor modulators.

Dampening of Excitatory Neurotransmitter Release

The decreased Ca^2+ influx directly translates into inhibition of synaptic vesicle exocytosis. This effect functionally limits the release of excitatory neurotransmitters, such as Glutamate, from the presynaptic terminal. By suppressing these chemical signals, the mechanism results in a modulated state within pathways associated with heightened physiological responses, thus stabilization of overactive nerve circuits.

Physiological Consequence: Systemic Modulation

The cumulative effect of reducing excitatory input at the synapse is the systemic modulation of neuronal hyperexcitability within the central nervous system. This action limits the propagation of excessive electrical activity across neural pathways, leading to physiological adjustments that reflect the drug’s mechanism of action.

Dosage and Administration Information

How to Use Vultin: Official Administration Guidelines

Administration of Vultin (gabapentin) follows procedural protocols to maintain steady plasma concentrations. The only approved route of administration is oral, but dosing schedules and specific handling instructions vary based on the drug's formulation and the patient’s clinical status.


Administration Scope Guideline Overview
Route of Administration Oral administration (capsules, tablets, oral solution).
Dosing Schedule Therapy begins with a gradual dose titration over a minimum of three days. The maintenance dose range for adults is typically 900 mg to 3600 mg daily, as determined by the specific condition being addressed.
Frequency and Timing Immediate-release formulations must be taken three times daily (TID). The time interval between doses must not exceed 12 hours to ensure proper drug concentration in the body.
Timing in Relation to Meals Immediate-release forms can be taken with or without food. Extended-release tablets must be taken with a meal.

Population-Specific Use and Procedural Steps

The official protocol requires mandatory dose adjustments in specific populations:

  • Renal Impairment: Dosing for adults and adolescents 12 years and older must be reduced in proportion to the patient’s calculated creatinine clearance (CrCl). Patients on hemodialysis require a supplemental dose following each 4-hour session.
  • Pediatric Patients: Dosing for children 3 to 11 years of age is calculated based on body weight, administered in three divided doses per day.

Special Handling and Course Duration

Special procedural conditions mandate that extended-release tablets must be swallowed whole and should not be split, crushed, or chewed. If discontinuing Vultin therapy, the dose must be gradually reduced (tapered) over a minimum period of at least one week.

Recent Clinical Evidence

Research evidence / Overview of studies for Vultin


Evidence for Vultin in Nerve Pain

The research on Vultin for nerve pain was primarily studied for conditions like Postherpetic Neuralgia (PHN), a condition characterized by nerve pain following a shingles infection. Research on these conditions where symptoms may vary in intensity included short-term, placebo-controlled randomized controlled trials (RCTs). These studies typically involved adults and research examined outcomes related to physical discomfort over study periods generally lasting 4 to 16 weeks.

In these trials, research explored changes in outcomes describing episodic or acute changes by measuring pain severity using standardized rating scales. Studies tracked outcomes related to physical discomfort, including the number of participants who achieved pre-specified levels of reduction (such as 50%) in their reported pain scores. Research highlights changes measured during the study period across the observed populations. However, follow-up durations were limited in most of the pivotal clinical trials. Comparative evidence remains limited for some of the other less-common types of nerve pain.


Evidence for Vultin in Partial Seizures

Vultin was evaluated in studies observing responses over defined time intervals. Research examined both adjunctive therapy (add-on to existing medication) and monotherapy (used alone) in populations with partial-onset seizures. The evidence base was evaluated in conditions characterized by fluctuating or episodic manifestations, with studies including populations across a broad range of ages, including adults, adolescents, and pediatric patients.

Research examined outcomes describing episodic or acute changes, including the percentage change in seizure frequency. Studies explored the proportion of participants who reached key milestones, such as a ge50% reduction in the number of seizure events. The duration of core primary endpoint trials is often relatively short. There is limited information for long-term outcomes regarding the sustained lack of seizure events or sustained changes in seizure frequency over many years.

Frequently Asked Questions (FAQ)

Common questions about Vultin (FAQ)

Q: Is Vultin the same kind of medicine as [similar drug name]?

Vultin belongs to a pharmacological category known as a gabapentinoid, and its active ingredient, Gabapentin, is structurally related to the neurotransmitter GABA. While other medicines may also be used to treat nerve pain or seizures, Vultin is distinct because official documents describe its mechanism as specifically modulating certain calcium channels on nerve endings.

Q: Are there any common foods or drinks that should be avoided while taking Vultin?

Official product information notes that taking Vultin with alcohol or other central nervous system (CNS) depressants may increase the risk of side effects like drowsiness. Regulatory constraints note that certain aluminum- and magnesium-containing antacids can reduce Vultin's absorption, and official guidance describes separating their administration by at least two hours. Regulatory documents do not list specific interactions with common foods or other non-alcoholic drinks.

Q: Are there generic versions of Vultin available?

Vultin is the brand name for the active ingredient, Gabapentin. Gabapentin, the active ingredient, is widely available in generic forms. Regulatory standards indicate that generic products must meet the same quality and performance specifications as the brand name.

Q: How quickly can a person expect to feel the effects of Vultin?

When taken orally, the concentration of Vultin in the blood typically reaches its peak within two to three hours. However, the exact time it takes to feel a clinical effect varies significantly, depending on the individual and the specific condition the medicine is being used to manage.

Q: Is Vultin a medicine that needs to be taken long-term?

Vultin is approved for chronic conditions like postherpetic neuralgia (nerve pain) and as a treatment for partial seizures. Because the conditions it addresses often require ongoing care, the medicine is commonly prescribed for long-term management. Discontinuation, if necessary, is described in official guidelines as requiring a gradual reduction (tapering) of the dose over time.

Q: Does Vultin cause weight gain, according to studies?

In clinical trials, weight gain has been reported as a common adverse reaction in a small percentage of patients. Additionally, peripheral edema (swelling in the hands or feet), which is also a common side effect, may contribute to perceived weight changes.

Q: Is Vultin considered a controlled substance?

Federally, Vultin (Gabapentin) is not classified as a controlled substance by the DEA. However, certain individual states in the United States have categorized it as a Schedule V controlled substance due to documented instances of misuse or dependence risk.

Q: Does Vultin have known interactions with common over-the-counter pain relievers?

Official regulatory documents do not list specific pharmacokinetic interactions with common over-the-counter pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs). However, due to Vultin's central nervous system (CNS) effects, such as drowsiness, the risk of increased sedation may be considered when combining it with other medicines that also cause drowsiness.

Q: Why do some people say Vultin helped them with a problem not listed in its main uses?

A medicine is approved by regulatory agencies for specific conditions (indications) based on defined clinical trial evidence. Once approved, the medicine may be used under a healthcare provider’s direction for other purposes beyond those specifically reviewed and approved by regulatory agencies.

Q: Can men and women expect different side effects from Vultin?

The official safety profile reports the overall frequency of adverse reactions observed across all study participants. The regulatory documents generally do not specify different expected side effect profiles for adult men and women.

Q: Does Vultin interact with herbal supplements like St. John's Wort?

Official drug interaction reports do not list specific interactions with St. John's Wort or other common herbal supplements. Because Vultin is cleared from the body by the kidneys and is not significantly broken down by the liver's main enzyme system (CYP450), the absence of CYP450 metabolism means it is not expected to interact through that specific pathway.

Q: What is the typical time frame to see the full potential of Vultin?

Vultin treatment begins with a gradual dose increase (titration) over several days until a stable maintenance dose is established by a healthcare provider. The full therapeutic potential of the medicine may not be observed until this stable dose is fully reached and maintained.

Q: Is there a known risk of dependence or addiction with Vultin?

While not controlled federally, some regulatory authorities have noted a potential for misuse, abuse, and the development of physical dependence. For this reason, official guidance recommends that discontinuation should involve a gradual reduction (tapering) of the dose.

Q: Is Vultin known to interact with caffeine?

Official drug interaction studies and product information do not list a specific interaction between Vultin and caffeine.

Q: Does Vultin require any special monitoring or regular blood tests?

Official guidelines require careful monitoring of patients for specific rare but serious adverse reactions, such as severe hypersensitivity reactions (DRESS). Additionally, since the medicine is cleared by the kidneys, individuals with reduced kidney function require monitoring of their creatinine clearance to inform appropriate dosage adjustments.

Q: Is Vultin generally well-tolerated?

The tolerability profile of Vultin is defined by the frequency of adverse effects reported in trials. The most common side effects include dizziness and somnolence (drowsiness). The side effect profile indicates that the medicine may be discontinued by patients if the adverse reactions become difficult to manage.

Q: Can Vultin affect the ability to drive or operate machinery?

Official warnings note that Vultin may cause very common side effects such as dizziness and somnolence (drowsiness). Official regulatory warnings note that patients should consider the potential impact of these side effects on activities that require mental focus, such as driving or operating machinery.

Q: Is Vultin known to cause any long-term organ damage?

The official safety profile is generally favorable for liver use because it is not metabolized by the liver. However, the regulatory label warns of rare, severe, multi-organ hypersensitivity reactions called DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) that can potentially affect internal organs.

Q: Can people with liver problems use Vultin?

Yes, Vultin is generally considered acceptable for individuals with liver impairment. Official documents note that the medicine is not metabolized (broken down) by the liver and is instead cleared primarily by the kidneys.

Q: Can taking Vultin make other pre-existing conditions worse?

Official regulatory warnings note that Vultin should be approached with caution in individuals who have mixed seizure disorders because, in rare cases, the medicine has been observed to potentially worsen absence seizures.

Q: Can Vultin interact with birth control pills?

Official studies have determined that Vultin does not affect the blood levels of the common active ingredients found in oral contraceptives. Therefore, it is not anticipated to reduce the effectiveness of birth control pills.

Q: What is the standard duration of treatment with Vultin?

The duration of treatment is determined by the prescribing healthcare provider based on the patient's specific condition. Since Vultin is indicated for chronic conditions like nerve pain and epilepsy, it is often prescribed for sustained periods of maintenance. Discontinuation, if necessary, requires a gradual reduction of the dose over time.

Q: How does Vultin differ from other medicines in the same class?

Vultin's primary mechanism of action involves specifically binding to a subunit on voltage-gated calcium channels in nerve endings. This modulates the release of excitatory neurotransmitters like Glutamate, which is a distinct way of stabilizing overactive nerve circuits compared to how many other nerve-affecting medicines operate.

Q: Can Vultin cause changes in appetite?

Official product information reports that an increase in appetite was noted as a common side effect in the pediatric population during clinical trials. This effect may be linked to subsequent weight changes in some individuals.

Q: How long does Vultin stay in your system after stopping?

The drug's elimination half-life, which is the time it takes for half of the medicine to be cleared from the bloodstream, is typically five to seven hours in adults with normal kidney function. Full clearance generally takes several half-lives.

How should Vultin be stored and disposed of?

Storage Conditions

Vultin (gabapentin) capsules and tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The oral solution, however, requires refrigerated storage between 2 C to 8 C (36 F to 46 F) and must not be frozen. All forms must be kept in the closed container they came in and protected from excess heat, light, and moisture.

Child Safety and Disposal

All Vultin products must be stored out of the sight and reach of children. Unused or expired medication should be disposed of using drug take-back programs when available. If not, it can be disposed of in the household trash by mixing it with an undesirable substance (such as used coffee grounds) and placing it in a sealed container. Vultin should not be flushed down a toilet or sink unless specifically instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vultin found in:

A-Z Index: